We are committed to all our shareholders with timely communications and maintaining best practices in corporate governance. Our corporate objectives are guided in creating value for our investors, advancing clinical translation of adipose derived stem cells, and ultimately enhancing the lives and lifestyles of as many people as possible.


    Avagenesis Corp. became a public company on Dec 18, 2013 through the reverse takeover of Westshire Capital Corp. (a Capital Pool Company) for a pre-money valuation of $20,623,950 plus a financing of $3,750,000 @$0.50 per common share.



    Fiscal Year End: June 30

    Auditors: KPMG LLP

    Avagenesis Corp. trades on the TSX Venture Exchange under the symbol VVA.


    Click here for the current stock quote and market capitalization for VVA


    Click here for recent news releases 


    Click here for SEDAR filed financial statements and MD&As


    Total Shares Outstanding: 53,017,371

    There are NO stock options issued

    and NO warrants outstanding

    Transfer & Escrow Agent: Computershare

    600, 530 - 8th Avenue SW

    Calgary, Alberta T2P 3S8 CANADA

    Toll Free: 800 564 6253

    Toll: +1 (514) 982 7555

    Fax Number: +1 (514) 982 7635 or +1 (888) 453 0330


    For further information, please contact Alan Tam, CPA, CA (CFO)

    Tel: (604) 377-7575

    Click here to email for more  info

    or sign-up for our investor newsletter below

    Certain statements contained in this website constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Avagenesis' current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Avagenesis may not successfully transition to a clinical stage company and the risk that Avagenesis may not successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Avagenesis. Avagenesis cautions the reader that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Avagenesis is not obligated to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.